Search research articles
Contact Us
Filters
Showing results (71-80 of 90) with videos related to
Page
of 9
Sort By:
Investigational New Drugs
|
February 7, 2024
CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial
Andrew J Armstrong, Ravit Geva, Hyun Cheol Chung, et al.
Biomedicines
|
February 25, 2023
A Lymph Node Ratio Model for Prognosis of Patients with Pancreatic Neuroendocrine Tumors
Esther Osher, Eiman Shalabna, Joseph M Klausner, et al.
Cancer Immunology, Immunotherapy : CII
|
August 6, 2024
Safety and clinical activity of JNJ-78306358, a human leukocyte antigen-G (HLA-G) x CD3 bispecific antibody, for the treatment of advanced stage solid tumors
Ravit Geva, Maria Vieito, Jorge Ramon, et al.
British Journal of Cancer
|
June 30, 2018
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012
Ranee Mehra, Tanguy Y Seiwert, Shilpa Gupta, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
August 7, 2023
Collaborative privacy-preserving analysis of oncological data using multiparty homomorphic encryption
Ravit Geva, Alexander Gusev, Yuriy Polyakov, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 4, 2023
Pembrolizumab for previously treated, microsatellite instability-high/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164
Dung T Le, Luis A Diaz, Tae Won Kim, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
March 27, 2019
Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
Yung-Jue Bang, Yoon-Koo Kang, Daniel V Catenacci, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 13, 2021
Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial
Bruno Bockorny, Teresa Macarulla, Valerya Semenisty, et al.
Cancer Research Communications
|
February 26, 2026
Lenvatinib Plus Pembrolizumab for Patients With Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results From the Phase 2 LEAP-005 Study
Mariano Ponz-Sarvisé, Sun Young Rha, Carlos A Gomez-Roca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 15, 2019
Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164
Dung T Le, Tae Won Kim, Eric Van Cutsem, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 90) with videos related to
Sort By:
Page
of 9
Investigational New Drugs
|
February 7, 2024
CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial
Andrew J Armstrong, Ravit Geva, Hyun Cheol Chung, et al.
Biomedicines
|
February 25, 2023
A Lymph Node Ratio Model for Prognosis of Patients with Pancreatic Neuroendocrine Tumors
Esther Osher, Eiman Shalabna, Joseph M Klausner, et al.
Cancer Immunology, Immunotherapy : CII
|
August 6, 2024
Safety and clinical activity of JNJ-78306358, a human leukocyte antigen-G (HLA-G) x CD3 bispecific antibody, for the treatment of advanced stage solid tumors
Ravit Geva, Maria Vieito, Jorge Ramon, et al.
British Journal of Cancer
|
June 30, 2018
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012
Ranee Mehra, Tanguy Y Seiwert, Shilpa Gupta, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
August 7, 2023
Collaborative privacy-preserving analysis of oncological data using multiparty homomorphic encryption
Ravit Geva, Alexander Gusev, Yuriy Polyakov, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 4, 2023
Pembrolizumab for previously treated, microsatellite instability-high/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164
Dung T Le, Luis A Diaz, Tae Won Kim, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
March 27, 2019
Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
Yung-Jue Bang, Yoon-Koo Kang, Daniel V Catenacci, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 13, 2021
Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial
Bruno Bockorny, Teresa Macarulla, Valerya Semenisty, et al.
Cancer Research Communications
|
February 26, 2026
Lenvatinib Plus Pembrolizumab for Patients With Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results From the Phase 2 LEAP-005 Study
Mariano Ponz-Sarvisé, Sun Young Rha, Carlos A Gomez-Roca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 15, 2019
Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164
Dung T Le, Tae Won Kim, Eric Van Cutsem, et al.
Page
of 9